Markers of gastrointestinal diseases
V. L. Ostanko,
T. P. Kalacheva,
K. A. Kulumaeva,
N. A. Li,
E. V. Beloborodova,
I. L. Purlik,
E. V. Kalyuzhina,
N. G. Brazovskaya,
V. V. Kalyuzhin https://doi.org/10.20538/1682-0363-2024-4-177-186
Abstract
The lifestyle of people nowadays and poor diet are factors affecting the increasing incidence of digestive diseases in people all over the world. The search for new methods of early diagnosis of the disease is an urgent issue of modern medicine. In the last decade, much attention has been paid to various biological markers that can be used to assess the risk of disease development, the response to therapy, and the possible development of complications. Biomarkers in clinical medicine can be used as additional tools not only to improve early diagnosis of gastrointestinal diseases but also to assess the effectiveness of therapy.
The aim of this lecture was to analyze and systematize biomarkers in various gastrointestinal diseases.
About the Authors
V. L. Ostanko
Siberian State Medical University
Russian Federation
Russian Federation
2, Moscow Trakt, Tomsk, 634050
T. P. Kalacheva
Siberian State Medical University
Russian Federation
Russian Federation
2, Moscow Trakt, Tomsk, 634050
K. A. Kulumaeva
Siberian State Medical University
Russian Federation
Russian Federation
2, Moscow Trakt, Tomsk, 634050
N. A. Li
Regional Oncology Center
Russian Federation
Russian Federation
115, Lenina Av., Tomsk, 634050
E. V. Beloborodova
Siberian State Medical University
Russian Federation
Russian Federation
2, Moscow Trakt, Tomsk, 634050
I. L. Purlik
Siberian State Medical University
Russian Federation
Russian Federation
2, Moscow Trakt, Tomsk, 634050
E. V. Kalyuzhina
Siberian State Medical University
Russian Federation
Russian Federation
2, Moscow Trakt, Tomsk, 634050
N. G. Brazovskaya
Siberian State Medical University
Russian Federation
Russian Federation
2, Moscow Trakt, Tomsk, 634050
V. V. Kalyuzhin
Siberian State Medical University
Russian Federation
Russian Federation
2, Moscow Trakt, Tomsk, 634050
References
1. Еганян Р.А., Кушунина Д.В., Калинина А.М. Актуальность и результативность раннего выявления заболеваний органов пищеварения при диспансеризации взрослого населения России. Профилактическая медицина. 2017;20(3):22– 27. DOI: 10.17116/profmed201720322-27.
2. Adamcova M., Šimko F. Multiplex biomarker approach to cardiovascular diseases. Acta Pharmacologica Sinica. 2018;39(7):1068–1072. DOI: 10.1038/aps.2018.29.
3. Ranjbar R., Ghasemian M., Maniati M., Khatami S.H., Jamali N., Taheri-Anganeh M. Gastrointestinal disorder biomarkers. Clinica Chimica Acta. 2022;530:13–26. DOI: 10.1016/j.cca.2022.02.013.
4. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics. 2001;69(3):89–95. DOI: 10.1067/mcp.2001.113989.
5. Садвакас А.С. Современные концепции идеальных биомаркеров в медицине. Современная медицина: актуальные вопросы. 2014;5(31):230–231.
6. Козлова И.В., Кудишина М.М., Пахомова А.Л. Биомаркеры воспалительных заболеваний кишечника. Экспериментальная и клиническая гастроэнтерология. 2018;157(9):4– 9. DOI: 10.31146/1682-8658-ecg-157-9-4-9.
7. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); 2016. Predictive Biomarker. 2016.URL: https://www.ncbi.nlm.nih.gov/books/NBK402283/Co-published by National Institutes of Health (US), Bethesda (MD).
8. Варванина Г.Г., Лесько К.А., Бордин Д.С., Дубцова Е.А., Малых М.В., Носкова К.К. и др. Диагностическое значение биомаркеров и компьютерной томографии в дифференциальной диагностике рака поджелудочной железы и хронического панкреатита. Доказательная гастроэнтерология. 2021;10(4):12–21. DOI: 10.17116/dokgastro20211004112.
9. Fu S., Wu D., Jiang W., Li J., Long J., Jia C. et al. Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives. Frontiers in Pharmacology. 2020;10:1667. DOI: 10.3389/fphar.2019.01667.
10. Конради А.О. Биомаркеры, их типы и основы применения в персонализированной медицине. Российский журнал персонализированной медицины. 2022;2(3):6–16. DOI: 10.18705/2782-3806-2022-2-3-6-16.
11. Baniak N., Senger J.L., Ahmed S., Kanthan S.C., Kanthan R. Gastric biomarkers: a global review. World Journal of Surgical Oncology. 2016;14(1):212. DOI: 10.1186/s12957-016-0969-3.
12. Durães C., Almeida G.M., Seruca R., Oliveira C., Carneiro F. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Archiv. 2014;464(3):367–378. DOI: 10.1007/s00428-013-1533-y.
13. Бакулина Н.В., Тихонов С.В., Лищук Н.Б. Хронический гастрит и функциональная диспепсия. Единство и борьба двух противоположностей. Медицинский совет. 2021;(15):164– 174. DOI: 10.21518/2079-701X-2021-15-164-174.
14. Цуканов В.В., Тонких Ю.Л., Васютин А.В., Перетятько О.В., Пуликов А.С., Барон И.И. Структура слизистой оболочки желудка у пациентов с различными концентрациями и соотношениями пепсиногенов в сыворотке крови. Медицинский совет. 2018;(14):114–117. DOI: 10.21518/2079-701X-2018-14-114-117.
15. Корноухова Л.А., Эмануэль В.Л., Денисов Н.Л., Никонов Е.Л. Инфекция Нelicobacter pylori: место серологической и культуральной диагностики в клинических рекомендациях. Клиническая лабораторная диагностика. 2021;66(8):496– 501. DOI: 10.51620/0869-2084-2021-66-8-496-501.
16. Tu H., Sun L., Dong X., Gong Y., Xu Q., Jing J. et al. A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A MultiPhase Study. The American Journal of Gastroenterology. 2017;112(5):704–715. DOI: 10.1038/ajg.2017.55.
17. Conti C.B., Agnesi S., Scaravaglio M., Masseria P., Dinelli M.E., Oldani M. et al. Early Gastric Cancer: Update on Prevention, Diagnosis and Treatment. International Journal of Environmental Research and Public Health. 2023;20(3):2149. DOI: 10.3390/ijerph20032149.
18. Куваев Р.О., Кашин C.В., Никонов Е.Л., Itoh T., Gotoda T., Gono K. Ранний рак желудка: современные методики скрининга, эндоскопической диагностики и малоинвазивного лечения. Доказательная гастроэнтерология. 2014;3(3):44–51.
19. Duan S., Rico K., Merchant J.L. Gastrin: from physiology to gastrointestinal malignancies. Function (Oxford, England). 2021;3(1):zqab062. DOI: 10.1093/function/zqab062.
20. Shen H., Xiong K., Wu X., Cheng S., Lou Q., Jin H. et al. The diagnostic alue of serum gastrin-17 and pepsinogen for gastric cancer screening in eastern China. Gastroenterology Research and Practice. 2021; 2021: 6894248. DOI: 10.1155/2021/6894248.
21. Бордин Д.С., Шенгелия М.И., Иванова В.А., Войнован И.Н. Helicobacter pylori: клиническое значение и принципы диагностики. Инфекционные болезни: новости, мнения, обучение. 2022;11(1):119–129. DOI: 10.33029/2305-3496-2022-11-1-119-129.
22. Ansari S., Yamaoka Y. Helicobacter pylori virulence factor cytotoxin-associated gene A (CagA)-mediated gastric pathogenicity. International Journal of Molecular Sciences. 2020;21(19):7430. DOI: 10.3390/ijms21197430.
23. Miernyk K.M., Bruden D., Rudolph K.M., Hurlburt D.A., Sacco F., McMahon B.J. et al. Presence of cagPAI genes and characterization of vacA s, i and m regions in Helicobacter pylori isolated from Alaskans and their association with clinical pathologies. Journal of Medical Microbiology. 2020;69(2):218–227. DOI: 10.1099/jmm.0.001123.
24. Muzaheed. Helicobacter pylori oncogenicity: mechanism, prevention, and risk factors. The Scientific World Journal. 2020;2020:1–10. DOI: 10.1155/2020/3018326.
25. Хавкин А.И., Новикова В.П., Шаповалова Н.С. Перспективные неинвазивные биомаркеры: интестинальные белки в диагностике повреждений слизистой оболочки кишечника. Экспериментальная и клиническая гастроэнтерология. 2021;188(4):155–160. DOI: 10.31146/1682- 8658-ecg-188-4-155-160.
26. Приходченко Н.Г., Шуматова Т.А., Зернова Е.С., Ни А.Н., Сергеева Е.В. Фекальные биомаркеры: диагностическая значимость и перспективы при аллергических заболеваниях желудочно-кишечного тракта. Медицинский оппонент. 2022;4(20):42–48.
27. Звягин А.А., Бавыкина И.А., Настаушева Т.Л., Бавыкин Д.В. Интестинальный белок, связывающий жирные кислоты, как перспективный маркер проницаемости тонкой кишки. Российский вестник перинатологии и педиатрии. 2020;65(6):29–33. DOI: 10.21508/1027-4065-2020-65-6-29-33.
28. Funaoka H., Kanda T., Fujii H. Intestinal fatty acid-binding protein (I-FABP) as a new biomarker for intestinal diseases. Rinsho Byori the Japanese Journal of Clinical Pathology. 2010;58(2):162–168.
29. Ливзан М.А., Гаус О.В. Содержание фекального зонулина – биомаркер синдрома кишечной проницаемости у больных синдромом раздраженного кишечника (обзор и результаты пилотного исследования). Доказательная гастроэнтерология. 2021;10(3):47–55. DOI: 10.17116/dokgastro20211003147.
30. Adriaanse M.P., Leffler D.A., Kelly C.P., Schuppan D., Najarian R.M., Goldsmith J.D. et al. Serum I-FABP detects gluten responsiveness in adult celiac disease patients on a short-term gluten challenge. The American Journal of Gastroenterology. 2016;111(7):1014–1022. DOI: 10.1038/ajg.2016.162.
31. Schurink M., Kooi E.M., Hulzebos C.V., Kox R.G., Groen H., Heineman E. et al. Intestinal fatty acid-binding protein as a diagnostic marker for complicated and uncomplicated necrotizing enterocolitis: a prospective cohort study. PLoS One. 2015;10(3). DOI: 10.1371/journal.pone.0121336.
32. Veres-Székely A., Szász C., Pap D., Szebeni B., Bokrossy P., Vannay Á. Zonulin as a potential therapeutic target in microbiota-gut-brain axis disorders: encouraging results and emerging questions. The International Journal of Molecular Sciences. 2023;24(8):7548. DOI: 10.3390/ijms24087548.
33. Fasano A., Not T., Wang W., Uzzau S., Berti I., Tommasini A. et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet. 2000;355(9214):1518–1519. DOI: 10.1016/S0140-6736(00)02169-3.
34. Haghbin M., Rostami-Nejad M., Forouzesh F., Sadeghi A., Rostami K., Aghamohammadi E. et al. The role of CXCR3 and its ligands CXCL10 and CXCL11 in the pathogenesis of celiac disease. Medicine (Baltimore). 2019;98(25):e15949. DOI: 10.1097/MD.0000000000015949.
35. Rezazadegan M., Soheilipour M., Tarrahi M.J., Amani R. Correlation Between Zinc Nutritional Status with Serum Zonulin and Gastrointestinal Symptoms in Diarrhea-Predominant Irritable Bowel Syndrome: A Case-Control Study. Digestive Diseases and Sciences. 2022;67(8):3632–3638. DOI: 10.1007/s10620-021-07368-6.
36. Zhang Y.G., Xia Y., Lu R., Sun J. Inflammation and intestinal leakiness in older HIV+ individuals with fish oil treatment. Genes & Diseases. 2018;5(3):220–225. DOI: 10.1016/j.gendis.2018.07.001.
37. Li J., Xu M., Qian W., Ling F., Chen Y., Li S. et al. Clinical value of fecal calprotectin for evaluating disease activity in patients with Crohn’s disease. Frontiers in Physiology. 2023;14: 1186665. DOI: 10.3389/fphys.2023.1186665.
38. Ayling R.M., Kok K. Fecal calprotectin. Advances in Clinical Chemistry. 2018;87:161–190. DOI: 10.1016/bs.acc.2018.07.005.
39. Rokkas T., Portincasa P., Koutroubakis I.E. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis. The Journal of Gastrointestinal and Liver Diseases. 2018;27(3):299–306. DOI: 10.15403/jgld.2014.1121.273.pti.
40. Cordes F., Demmig C., Bokemeyer A., Brückner M., Lenze F., Lenz P. et al. MicroRNA-320a monitors intestinal dis ease activity in patients with inflammatory bowel disease. Clinical and Translational Gastroenterology. 2020;11(3):e00134. DOI: 10.14309/ctg.0000000000000134.
41. Morilla I., Uzzan M., Laharie D., Cazals-Hatem D., Denost Q., Daniel F. et al. Colonic microRNA profiles, identified by a deep learning algorithm, that predict responses to therapy of patients with acute severe ulcerative colitis. Clinical Gastroenterology and Hepatology. 2019;17(5):905–913. DOI: 10.1016/j.cgh.2018.08.068.
42. Teschke R. Alcoholic liver disease: alcohol metabolism, cascade of molecular mechanisms, cellular targets, and clinical aspects. Biomedicines. 2018;6(4):106. DOI: 10.3390/biomedicines6040106.
43. Zeng M., Chen L., Li Y., Mi Y., Xu L. Problems and challenges associated with renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease. Medicine (Baltimore). 2023;3(3):105–113. DOI: 10.1097/ID9.0000000000000085.
44. Llewellyn H.P., Vaidya V.S., Wang Z., Peng Q., Hyde C., Pot ter D. et al. Evaluating the sensitivity and specificity of promising circulating biomarkers to diagnose liver injury in humans. The Journal of Toxicological Sciences. 2021;181(1):23–34. DOI: 10.1093/toxsci/kfab003.
45. Church R.J., Kullak-Ublick G.A., Aubrecht J., Bonkovsky H.L., Chalasani N., Fontana R.J. et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. Journal of Hepatology. 2019;69(2):760–773. DOI: 10.1002/hep.29802.
46. Lehmann-Werman R., Magenheim J., Moss J., Neiman D., Abraham O., Piyanzin S. et al. Monitoring liver damage using hepatocyte-specific methylation markers in cell-free circulating DNA. JCI Insight. 2018;3(12):e120687. DOI: 10.1172/jci.insight.120687.
47. Kan Changez M.I., Mubeen M., Zehra M., Samnani I., Abdul Rasool A., Mohan A. et al. Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review. Journal of International Medical Research. 2023;51(9):3000605231197058. DOI: 10.1177/03000605231197058.
48. Lilly A.C., Astsaturov I., Golemis E.A. Intrapancreatic fat, pancreatitis, and pancreatic cancer. Cellular and Molecular Life Sciences. 2023;80(8):206. DOI: 10.1007/s00018-023-04855-z.
49. Aune D., Mahamat-Saleh Y., Norat T., Riboli E. High Body Mass Index and Central Adiposity Is Associated with Increased Risk of Acute Pancreatitis: A Meta-Analysis. Digestive Diseases and Sciences. 2021;66(4):1249–1267. DOI: 10.1007/s10620-020-06275-6.
50. O’Neill R.S., Stoita A. Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket? World Journal of Gastroenterology. 2021;27(26):4045–4087. DOI: 10.3748/wjg.v27.i26.4045.
51. Pereira S.P., Oldfield L., Ney A., Hart P.A., Keane M.G., Pandol S.J. et al. Early detection of pancreatic cancer. The Lancet Gastroenterology and Hepatology. 2020;5(7):698–710. DOI: 10.1016/S2468-1253(19)30416-9.
52. Binicier O.B., Pakoz Z.B. CA 19-9 levels in patients with acute pancreatitis due to gallstone and metabolic/toxic reasons. Revista da Associacao Medica Brasileira. 2019;65(7):965–970. DOI: 10.1590/1806-9282.65.7.965.
53. Lee T., Teng T.Z.J., Shelat V.G. Carbohydrate antigen 19-9-tumor marker: Past, present, and future. World Journal of Gastrointestinal Surgery. 2020;12(12):468–490. DOI: 10.4240/wjgs.v12.i12.468.
54. Janga L.S.N., Sambe H.G., Yasir M., Man R.K., Gogikar A., Nanda A. et al. Holistic Understanding of the Role of Carbohydrate Antigen 19-9 in Pancreatic Cancer Screening, Early Diagnosis, and Prognosis: A Systematic Review. Cureus Journal of Medical Science. 2023;15(8):e44382. DOI: 10.7759/cureus.44382.
55. Liang Y., Chang S., Guo H., Man Q., Zang F., Gao S. Presence of tumor deposits is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma. The American Journal of Cancer Research. 2023;13(5):1970–1984.
56. Dong D., Jia L., Zhang L., Ma N., Zhang A., Zhou Y. et al. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer. Cancer Science. 2018;109:2841–2851. DOI: 10.1111/cas.13712.
57. Gu Y.L., Lan C., Pei H., Yang S.N., Liu Y.F., Xiao L.L. Applicative value of sdrum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis for patients with pancreatic cancer treated by concurrent chemoradiotherapy. The Asian Pacific Journal of Cancer Prevention. 2015;16(15):6569–6573. DOI: 10.7314/apjcp.2015.16.15.6569.
Review
For citations:
Ostanko V.L., Kalacheva T.P., Kulumaeva K.A., Li N.A., Beloborodova E.V., Purlik I.L., Kalyuzhina E.V., Brazovskaya N.G., Kalyuzhin V.V. Markers of gastrointestinal diseases. Bulletin of Siberian Medicine. 2024;23(4):177-186. https://doi.org/10.20538/1682-0363-2024-4-177-186
Views:
236
Email this article 